Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Most drug/label-concordant statements were accurate (indication, mechanism, general adjunct use, pancreatitis observation, hypoglycemia risk with insulin/secretagogues, hypersensitivity/bullous pemphigoid/pancreatitis as postmarketing events). Several side-effect claims were unsupported or overly specific (URTI, nasopharyngitis, headache). Non-label administrative/market/patent statements were not relevant to prescribing information and reduced alignment.
Category Scores
Accurate Statements
Januvia is a prescription medication used to improve blood sugar control in adults with type 2 diabetes.
INDICATIONS AND USAGE: indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Januvia is typically used in combination with diet and exercise.
INDICATIONS AND USAGE: adjunct to diet and exercise to improve glycemic control.
Januvia may be used with other diabetes medications.
Not explicitly stated in the provided indication excerpt, but supported by the presence of combination regimens in the Clinical Studies section excerpts and combination use discussion in Adverse Reactions (clinical trials experience) excerpts.
Januvia is also known by the generic name sitagliptin.
DESCRIPTION/Active ingredient: JANUVIA contains sitagliptin phosphate; DPP-4 inhibitor description consistent with sitagliptin.
Januvia is a dipeptidyl peptidase-4 (DPP-4) inhibitor.
DESCRIPTION and 12.1 Mechanism of Action: orally-active inhibitor of the DPP-4 enzyme.
Januvia works by increasing the levels of incretin hormones.
12.1 Mechanism of Action: slowing the inactivation of incretin hormones; increasing and prolonging the action of these hormones.
By blocking the enzyme DPP-4, Januvia helps keep more incretin hormones active.
12.1 Mechanism of Action: sitagliptin is a DPP-4 inhibitor slowing inactivation of incretin hormones.
Keeping incretin hormones active leads to lower blood sugar levels.
INDICATIONS/Clinical Studies excerpts: improvement in hemoglobin A1C and glucose parameters; Mechanism excerpt describes prolonged incretin action.
More serious side effects of Januvia can include pancreatitis.
5.1 Pancreatitis: postmarketing reports of acute pancreatitis; observe and discontinue if suspected.
More serious side effects of Januvia can include allergic reactions.
4 CONTRAINDICATIONS and 5.5 Hypersensitivity Reactions: serious hypersensitivity reactions including anaphylaxis/angioedema; discontinue and institute alternative treatment.
More serious side effects of Januvia can include low blood sugar (hypoglycemia).
5.4 Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues: increased incidence; also reflected in Adverse Reactions excerpt.
Low blood sugar (hypoglycemia) with Januvia can occur particularly when used with other diabetes medications like sulfonylureas or insulin.
5.4: incidence increased with insulin or insulin secretagogues (e.g., sulfonylurea); may require lower dose to reduce risk.
There have been postmarketing reports of pancreatitis, and after initiation patients should be observed for signs and symptoms of pancreatitis.
5.1 Pancreatitis: observe carefully; discontinue promptly if suspected.
Sitagliptin is modestly dialyzable.
10 OVERDOSAGE: modestly dialyzable; 13.5% removed over hemodialysis session.
Unsupported Statements
Common side effects of Januvia include upper respiratory tract infection.
The provided label excerpts do not list upper respiratory tract infection as a common adverse reaction.
Common side effects of Januvia include nasopharyngitis.
The provided label excerpts do not list nasopharyngitis as a common adverse reaction.
Common side effects of Januvia include headache.
The provided label excerpts do not list headache as a common adverse reaction.
Generic versions of Januvia may become available once patents expire.
Patent/market exclusivity and generic availability are not addressed in the provided prescribing information excerpts.
Generic sitagliptin availability can offer a more affordable treatment option for patients.
Affordability/price impact is not stated in the provided prescribing information excerpts.
Information on specific patent expiry dates for Januvia can be found on DrugPatentWatch.com.
External resource/patent expiry tooling is not present in the provided prescribing information excerpts.
Patent challenges and the potential for generic competition can influence the market exclusivity of the drug.
Market exclusivity/patent challenges are not addressed in the provided prescribing information excerpts.
Contradictions
Important Omissions
Recommended JANUVIA dosage (100 mg once daily) and that it can be taken with or without food.
Importance:
Moderate
Renal impairment dosing adjustments (eGFR-based 50 mg/25 mg and instruction to assess renal function prior to initiation and periodically).
Importance:
Moderate
Contraindication: history of a serious hypersensitivity reaction to sitagliptin (e.g., anaphylaxis or angioedema).
Importance:
Moderate
Label limitations of use: should not be used in patients with type 1 diabetes.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Safety-related statements included pancreatitis and hypoglycemia risk with insulin/secretagogues, but several common-side-effect claims are unsupported by the provided excerpts, and the contraindication/Type 1 diabetes limitation were omitted, which could affect label-accurate risk framing.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several 'common side effects' (URTI, nasopharyngitis, headache) are not supported by the provided prescribing information excerpts, and key label elements (contraindication, Type 1 diabetes limitation, specific dosing/renal dosing) were omitted.
Suggested Improvement
Remove or rephrase side-effect claims to match label-listed adverse reactions, and include the label-mandatory elements from the provided excerpts: adjunct indication, limitation of use (no Type 1 diabetes), hypersensitivity contraindication, and the recommended dosing/renal impairment dosing and renal-function assessment.